Medical Mycology Case Reports, published by Elsevier, is a pivotal journal dedicated to advancing the field of mycology through the presentation of case reports that highlight clinical findings, diagnostic challenges, and treatment outcomes associated with fungal infections. With its ISSN 2211-7539 and E-ISSN 2211-7539, this open-access journal has been serving the global community since 2012, allowing unrestricted access to its valuable insights. Situated in the Netherlands, specifically at RADARWEG 29, AMSTERDAM, this journal has gained recognition in areas such as Infectious Diseases (ranked Q3) and Microbiology (ranked Q4) as of 2023. Its commitment to disseminating high-quality research is reflected in its Scopus rankings, which place it at the 51st percentile in Medicine and the 32nd percentile in Immunology and Microbiology. By bridging the gap between clinical cases and academic research, Medical Mycology Case Reports plays a crucial role in enriching the knowledge base of practitioners and researchers alike, ultimately contributing to improved patient management and public health.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Case Reports in Gastrointestinal Medicine, published by HINDAWI LTD, is a leading open-access journal dedicated to the dissemination of significant findings in the field of gastrointestinal medicine. Established in 2011, this journal champions the accessibility of scholarly work, allowing researchers, professionals, and students to explore vital case studies that enhance clinical understanding and patient care across various gastrointestinal conditions. With an emphasis on innovative practices and advances in treatment, the journal serves as an invaluable resource for those committed to furthering their knowledge and improving outcomes in gastrointestinal health. By promoting the robust sharing of case reports and clinical insights, Case Reports in Gastrointestinal Medicine not only contributes to the academic community but also supports practitioners in their quest for evidence-based practice.

BMJ Case Reports is a vital resource within the field of medicine, published by the esteemed BMJ PUBLISHING GROUP. With an E-ISSN of 1757-790X and a focus on disseminating high-quality case reports, this journal serves as a platform for healthcare professionals, researchers, and students to share unique clinical experiences and uncommon presentations of medical conditions. Since its inception in 2008 and continuing through 2024, it has gained recognition for contributing to the advancement of medical knowledge, currently ranking at Q4 in the Medicine (miscellaneous) category and positioned in the 54th percentile in General Medicine according to Scopus rankings. Although it is a subscription-based journal, its impact on clinical practice and education is significant, enabling practitioners to learn from diverse case studies and improving patient care outcomes. As it aims to enhance the understanding of rare and significant medical cases, BMJ Case Reports remains an essential publication for those at the forefront of medical innovation.

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

AME Case Reports, published by AME PUBLISHING COMPANY, is a peer-reviewed open-access journal dedicated to the dissemination of high-quality clinical case reports across various medical disciplines. With an expanding focus on innovative medical practices and clinical experiences, this journal serves as an essential platform for healthcare professionals, researchers, and medical students to share significant findings and insights that contribute to evidence-based practices. Although specific metrics such as impact factors and H-index are not currently available, the journal's commitment to academic rigor and accessibility fosters an environment for scholarly exchange and professional development. The publication facilitates immediate access to important case studies that may inform clinical decisions and improve patient care. In an era where sharing specialized knowledge is paramount, AME Case Reports stands as a vital resource for those involved in the medical community worldwide.

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

Cancer Radiotherapie, published by Elsevier, is a respected academic journal dedicated to advancing the field of oncology and radiology through original research and comprehensive reviews. With an ISSN of 1278-3218 and an E-ISSN of 1769-6658, the journal serves as a vital platform for disseminating knowledge and innovation in cancer treatment methodologies, specifically focusing on radiotherapy. As of 2023, it holds a Category Quartile of Q3 in both Oncology and Radiology, Nuclear Medicine and Imaging, reflecting its significance within these domains amidst a competitive landscape. Despite its current rankings—205th out of 333 in Radiology and 269th out of 404 in Oncology—it continuously strives to build a reputable presence with contributions that push the boundaries of cancer therapy. Although open access options are not available, the journal is committed to ensuring that valuable insights reach healthcare professionals and researchers worldwide, contributing to improved patient outcomes and advancements in treatment efficacy.